Gilead Joins Up With Yale In Cancer Discovery Collaboration
This article was originally published in The Pink Sheet Daily
The biotech has partnered with Yale University on cancer research in a deal that could provide $100 million in funding to Yale over 10 years.
You may also be interested in...
Gilead, JAKed About Cancer Research, Buys YM BioScienses
Gilead will buy the Canadian cancer specialist for $510 million, gaining the lead drug CYT387, a JAK1/JAK2 inhibitor that has demonstrated positive results in myelofibrosis patients.
Gilead Springs Further Into Oncology With Calistoga Acquisition
Dominant in HIV, the biotech pays $375 million up front for Seattle-based Calistoga and its closely-watched PI3K program.
Pfizer Signs Up Seven New York Institutions To Create Biomedical Discovery Engine
New York deals follow UCSF tie-up in San Francisco; six more city-based alliances are to come.